Lupus & antiphospholipid syndrome
Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry
Authors' conclusion
BEL, in addition to SoC, controls disease activity, reduces GC use and suppresses organ damage in case of proliferative LN.
Study context
- Population
- Patients with biopsy-proven ISN/RPS class III or IV lupus nephritis (LN), with or without coexisting class V LN
- Participants
- 30 vs 32
- Exposure
- Belimumab (BEL) plus standard of care (SoC) vs SoC in induction therapy
- BEL+SoCn = 30
- SoCn = 32reference
- Outcome
- Complete renal response (CRR)
- Follow-up
- 52 weeks
Methodological detailsreal-world, LOOPS registry
- Real-world
- LOOPS registry
Main finding
As reported in the abstract
CRR
- Significantly higher complete renal response (CRR) in BEL+SoC than SoC
Observational data: associations, not effects.
Further findings
BEL retention rate · 52 weeks
- 52-week retention rate of BEL
- 90.0%
Primary efficacy renal response · 52 weeks
- Significantly higher primary efficacy renal response achievement in BEL+SoC vs SoC
Glucocorticoid (GC) dosage and SLICC/ACR DI scores
- Significantly lower GC dosage and SLICC damage index scores in BEL+SoC vs SoC
Predictors of CRR at 52 weeks (multivariate analysis)
- SoC: lack of estimated glomerular filtration rate (eGFR) improvement at 4 weeks associated with CRR failure
- BEL+SoC: shorter duration (cut-off 42 days) between start of induction therapy and addition of BEL related to CRR
Original publication
Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry. Rheumatology (Oxford). Published 17 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →